Electrical Impedance Myography Correlates with Functional Measures of Disease Progression in D2-mdx Mice and Boys with Duchenne Muscular Dystrophy

被引:4
|
作者
Chrzanowski, Stephen M. [1 ,2 ]
Nagy, Janice A. [2 ]
Pandeya, Sarbesh [2 ]
Rutkove, Seward B. [2 ]
机构
[1] Boston Childrens Hosp, Dept Neurol, Boston, MA USA
[2] Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA
关键词
Electrical impedance myography; duchenne muscular dystrophy; D2-mdx mice; biomarker; functional outcome measures; HELD ELECTRODE ARRAY; QUANTITATIVE ULTRASOUND; MUSCLE; MANAGEMENT; DIAGNOSIS; ATROPHY;
D O I
10.3233/JND-210787
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Sensitive, objective, and longitudinal outcome measures applicable to both pre-clinical and clinical interventions are needed to assess muscle health in Duchenne muscular dystrophy (DMD). Electrical impedance myography (EIM) has the potential to non-invasively measure disease progression in mice and boys with DMD. Objective: We sought to evaluate how electrical impedance values (i.e., phase, reactance, and resistance) correlate to established measures of disease in both D2-mdx and wild type (WT) mice and boys with and without DMD. Methods: Histological, functional, and EIM data collected from previous studies of WT and D2-mdx mice at 6, 13, 21 and 43 weeks of age were reanalyzed. In parallel, previously collected functional outcome measures and EIM values were reanalyzed from boys with and without DMD at four different age groups from 2 to 14 years old. Results: In mice, disease progression as detected by histological, functional, andEIMmeasures, was appreciable over this time period and grip strength best correlated to longitudinal phase and reactance impedance values. In boys, disease progression quantified through commonly utilized functional outcome measures was significant and longitudinal phase demonstrated the strongest correlation with functional outcome measures. Conclusion: Similar changes in EIM values, specifically in longitudinal reactance and phase, were found to show significant correlations to functional measures in both mice and boys. Thus, EIM demonstrates applicability in both pre-clinical and clinical settings and can be used as a safe, non-invasive, and longitudinal proxy biomarker to assess muscle health in DMD.
引用
收藏
页码:81 / 90
页数:10
相关论文
共 33 条
  • [21] Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status
    McDonald, Craig M.
    Marden, Jessica R.
    Shieh, Perry B.
    Wong, Brenda L.
    Lane, Henry
    Zhang, Adina
    Nguyen, Ha
    Frean, Molly
    Trifillis, Panayiota
    Koladicz, Karyn
    Signorovitch, James
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (04)
  • [22] Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance
    Nair, Kavya S.
    Lott, Donovan J.
    Forbes, Sean C.
    Barnard, Alison M.
    Willcocks, Rebecca J.
    Senesac, Claudia R.
    Daniels, Michael J.
    Harrington, Ann T.
    Tennekoon, Gihan, I
    Zilke, Kirsten
    Finanger, Erika L.
    Finkel, Richard S.
    Rooney, William D.
    Walter, Glenn A.
    Vandenborne, Krista
    JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (03) : 423 - 436
  • [23] CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy
    Pinto-Mariz, Fernanda
    Carvalho, Luciana Rodrigues
    De Queiroz Campos Araujo, Alexandra Prufer
    De Mello, Wallace
    Ribeiro, Marcia Goncalves
    Soares Alves Cunha, Maria Do Carmo
    Cabello, Pedro Hernan
    Riederer, Ingo
    Negroni, Elisa
    Desguerre, Isabelle
    Veras, Mariana
    Yada, Erica
    Allenbach, Yves
    Benveniste, Olivier
    Voit, Thomas
    Mouly, Vincent
    Silva-Barbosa, Suse Dayse
    Butler-Browne, Gillian
    Savino, Wilson
    SKELETAL MUSCLE, 2015, 5
  • [24] Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease
    Eren, Selen Abanuz
    Tastan, Cihan
    Karadeniz, Kevser Buse
    Turan, Raife Dilek
    Cakirsoy, Didem
    Kancagi, Derya Dilek
    Yilmaz, Sevdican Ustun
    Oztatlici, Mustafa
    Oztatlici, Hulya
    Ozer, Samed
    Tumentemur, Gamze
    Baykal, Ahmet Tarik
    Ovali, Ercument
    CURRENT GENE THERAPY, 2023, 23 (04) : 304 - 315
  • [25] CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy
    Fernanda Pinto-Mariz
    Luciana Rodrigues Carvalho
    Alexandra Prufer De Queiroz Campos Araujo
    Wallace De Mello
    Márcia Gonçalves Ribeiro
    Maria Do Carmo Soares Alves Cunha
    Pedro Hernan Cabello
    Ingo Riederer
    Elisa Negroni
    Isabelle Desguerre
    Mariana Veras
    Erica Yada
    Yves Allenbach
    Olivier Benveniste
    Thomas Voit
    Vincent Mouly
    Suse Dayse Silva-Barbosa
    Gillian Butler-Browne
    Wilson Savino
    Skeletal Muscle, 5
  • [26] ELECTRICAL IMPEDANCE MYOGRAPHY IN INDIVIDUALS WITH COLLAGEN 6 AND LAMININ α-2 CONGENITAL MUSCULAR DYSTROPHY: A CROSS-SECTIONAL AND 2-YEAR ANALYSIS
    Nichols, Carmel
    Jain, Minal S.
    Meilleur, Katherine G.
    Wu, Tianxia
    Collins, James
    Waite, Melissa R.
    Dastgir, Jahannaz
    Salman, Anam
    Donkervoort, Sandra
    Duong, Tina
    Keller, Katherine
    Leach, Meganne E.
    Lott, Donovan J.
    Mcguire, Michelle N.
    Nelson, Leslie
    Rutkowski, Anne
    Vuillerot, Carole
    Bonnemann, Carsten G.
    Lehky, Tanya J.
    MUSCLE & NERVE, 2018, 57 (01) : 54 - 60
  • [27] The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.mdx mouse model of Duchenne muscular dystrophy
    Bellissimo, Catherine A.
    Gandhi, Shivam
    Castellani, Laura N.
    Murugathasan, Mayoorey
    Delfinis, Luca J.
    Thuhan, Arshdeep
    Garibotti, Madison C.
    Seo, Yeji
    Rebalka, Irena A.
    Hsu, Henry H.
    Sweeney, Gary
    Hawke, Thomas J.
    Abdul-Sater, Ali A.
    Perry, Christopher G. R.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2024, 326 (04): : C1011 - C1026
  • [28] Memory impairment in the D2.mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688
    Bellissimo, Catherine A.
    Castellani, Laura N.
    Finch, Michael S.
    Murugathasan, Mayoorey
    Gandhi, Shivam
    Sweeney, Gary
    Abdul-Sater, Ali A.
    MacPherson, Rebecca E. K.
    Perry, Christopher G. R.
    EXPERIMENTAL PHYSIOLOGY, 2023, 108 (09) : 1108 - 1117
  • [29] Mitochondrial creatine sensitivity is lost in the D2.mdx model of Duchenne muscular dystrophy and rescued by the mitochondrial-enhancing compound Olesoxime
    Bellissimo, Catherine A.
    Delfinis, Luca J.
    Hughes, Meghan C.
    Turnbull, Patrick C.
    Gandhi, Shivam
    DiBenedetto, Sara N.
    Rahman, Fasih A.
    Tadi, Peyman
    Amaral, Christina A.
    Dehghani, Ali
    Cobley, James N.
    Quadrilatero, Joe
    Schlattner, Uwe
    Perry, Christopher G. R.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 324 (05): : C1141 - C1157
  • [30] Characterization of Alzheimer's disease-like neuropathology in Duchenne's muscular dystrophy using the DBA/2J mdx mouse model
    Hayward, Grant C.
    Caceres, Daniela
    Copeland, Emily N.
    Baranowski, Bradley J.
    Mohammad, Ahmad
    Whitley, Kennedy C.
    Fajardo, Val A.
    MacPherson, Rebecca E. K.
    FEBS OPEN BIO, 2022, 12 (01): : 154 - 162